Onapristone extended-release compositions and methods
Onapristone extended-release formulations and methods of administering onapristone extended-release formulations are provided. Onapristone extended-release formulations provide sufficient therapeutic activity as compared to immediate-release formulations with reduced potential for adverse side effects.
1. An extended release pharmaceutical composition comprising about 5% (wt/wt) onapristone, wherein the onapristone is present in an amount from about 2 mg to about 50 mg, and wherein the C max of onapristone following the administration of the extended release formulation to a patient is at least about 240 ng/ml over about 8-12 hours.
2. The extended release pharmaceutical composition of claim 1 , wherein the dosage form of the pharmaceutical composition is selected from the group consisting of tablets and capsules.
3. The extended release pharmaceutical composition of claim 1 , wherein the purity of the onapristone is at least about 98%.
4. The extended-release pharmaceutical composition of claim 1 , wherein the ratio of onapristone to inactive excipients is about 0.05 to about 5% (wt/wt).
5. The extended release pharmaceutical composition of claim 1 , wherein the onapristone is present in an amount selected from the group consisting of about 2 mg, 2.5 mg, 5 mg, 10 mg, 20 mg, 25 mg, 37.5 mg, and 50 mg.
6. The extended release pharmaceutical composition of claim 1 , wherein the AUC of onapristone following the administration of 10 mg of the extended release formulation to a patient twice per day is at least about 1578 ng*h/ml over about 8-12 hours.
7. The extended release pharmaceutical composition of claim 1 , wherein a steady state plasma concentration is achieved at about 8 days following the administration of the extended release pharmaceutical composition to a patient twice per day.
8. The extended release pharmaceutical composition of claim 1 , wherein the composition comprises a cellulose.
9. The extended release pharmaceutical composition of claim 8 , wherein the cellulose comprises hydroxypropyl methylcellulose and microcrystalline cellulose.
10. A method of administering onapristone to a patient having cancer comprising administering an extended release onapristone pharmaceutical composition of claim 1 at least once per day to the patient.
11. The method of claim 10 , wherein the extended release onapristone pharmaceutical composition is administered twice per day.
12. The method of claim 10 , wherein the onapristone it at least about 98% pure.
13. The method of claim 10 , wherein the amount of onapristone in the extended release onapristone pharmaceutical composition is selected from the group consisting of about 2 mg, 2.5 mg, 5 mg, 10 mg, 20 mg, 25 mg, 37.5 mg and 50 mg.
14. The method of claim 10 , wherein the cancer expresses the progesterone receptor.
15. The method of claim 14 , wherein the cancer is selected from the group consisting of breast, prostate, ovarian, and uterine endometrioid cancers.
16. A method of treating a human subject having a disorder capable of treatment with onapristone comprising administering the extended release onapristone pharmaceutical composition of claim 1 to the human subject, wherein the AUC of onapristone following the administration of 10 mg of the extended release formulation to a patient is at least about 1578 ng*h/ml over about 8-12 hours, wherein the disorder is selected from the group consisting of breast cancer, endometrial cancer, prostate cancer, ovarian, uterine endometrioid cancers, and other types of cancer which express the progesterone receptor.
17. The method of claim 16 , wherein the extended release onapristone pharmaceutical composition is administered to the human subject once per day or twice per day.
18. A method of treating a human subject having a disorder capable of treatment with onapristone comprising administering to said subject 10 mg of the extended release onapristone pharmaceutical composition of claim 1 , wherein the Cmax of onapristone in the human subject is at least about 240 ng/ml over about 8-12 hours, wherein the disorder is selected from the group consisting of breast cancer, endometrial cancer, prostate cancer, ovarian, uterine endometrioid cancers, and other types of cancer which express the progesterone receptor.
19. The method of claim 18 , wherein the extended release onapristone pharmaceutical formulation is administered to the human subject once per day or twice per day.
20. A method of treating a human subject having a disorder capable of treatment with onapristone comprising administering to said subject the extended release pharmaceutical composition of claim 1 , wherein a steady state plasma concentration is achieved at about 8 days, wherein the disorder is selected from the group consisting of breast cancer, endometrial cancer, prostate cancer, ovarian, uterine endometrioid cancers, and other types of cancer which express the progesterone receptor.
21. The method of claim 20 , wherein the extended release onapristone pharmaceutical formulation is administered to the human subject once per day or twice per day.